HK20489A - Microencapsulation of water soluble polypeptides - Google Patents

Microencapsulation of water soluble polypeptides

Info

Publication number
HK20489A
HK20489A HK204/89A HK20489A HK20489A HK 20489 A HK20489 A HK 20489A HK 204/89 A HK204/89 A HK 204/89A HK 20489 A HK20489 A HK 20489A HK 20489 A HK20489 A HK 20489A
Authority
HK
Hong Kong
Prior art keywords
microencapsulation
water soluble
soluble polypeptides
water
biocompatable
Prior art date
Application number
HK204/89A
Other languages
English (en)
Inventor
John Scott Kent
Lynda Mary Sanders
Danny Harvey Lewis
Thomas Robert Tice
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK20489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of HK20489A publication Critical patent/HK20489A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK204/89A 1980-11-18 1989-03-09 Microencapsulation of water soluble polypeptides HK20489A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20786480A 1980-11-18 1980-11-18

Publications (1)

Publication Number Publication Date
HK20489A true HK20489A (en) 1989-03-17

Family

ID=22772297

Family Applications (1)

Application Number Title Priority Date Filing Date
HK204/89A HK20489A (en) 1980-11-18 1989-03-09 Microencapsulation of water soluble polypeptides

Country Status (15)

Country Link
EP (1) EP0052510B2 (ja)
JP (1) JPS57118512A (ja)
AT (1) ATE21624T1 (ja)
AU (1) AU556754B2 (ja)
CA (1) CA1176565A (ja)
DE (2) DE52510T1 (ja)
HK (1) HK20489A (ja)
IE (1) IE52003B1 (ja)
IL (1) IL64298A (ja)
MY (1) MY8700835A (ja)
NL (1) NL930001I2 (ja)
NZ (1) NZ198982A (ja)
PH (1) PH19942A (ja)
SG (1) SG94487G (ja)
ZA (1) ZA817973B (ja)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
AU567155B2 (en) * 1983-04-15 1987-11-12 Damon Biotech Inc. Capsules for releasing core material at constant rate
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
DE3428372A1 (de) * 1984-08-01 1986-02-13 Hoechst Ag, 6230 Frankfurt Mikrokapseln von regulatorischen peptiden mit kontrollierter freisetzung, verfahren zu ihrer herstellung und injektionszubereitungen
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US5169633A (en) * 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5059422A (en) * 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
CH669506A5 (en) * 1986-01-13 1989-03-31 Hugo Degen Oscillating and reclining furniture
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
DE3855869T2 (de) 1987-02-20 1997-10-02 Genentech Inc Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
ZA905327B (en) * 1989-07-07 1992-03-25 Sandoz Ltd Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CH679207A5 (ja) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5084443A (en) * 1989-12-04 1992-01-28 Biomeasure, Inc. Promoting expression of acetylcholine receptors with lhrh antagonist
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5258488A (en) * 1992-01-24 1993-11-02 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6005067A (en) * 1992-01-24 1999-12-21 Cargill Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6326458B1 (en) 1992-01-24 2001-12-04 Cargill, Inc. Continuous process for the manufacture of lactide and lactide polymers
US5247059A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for the manufacture of a purified lactide from esters of lactic acid
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5247058A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
DE4223169C1 (de) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Composition of microspheres with several delayed release nuclei and its preparation process.
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
DK0615555T3 (da) * 1992-10-02 2001-07-09 Cargill Inc Tekstilmateriale af smeltestabil lactidpolymer og fremgangsmåde til fremstilling deraf
US6005068A (en) 1992-10-02 1999-12-21 Cargill Incorporated Melt-stable amorphous lactide polymer film and process for manufacture thereof
DE69322155T2 (de) * 1992-10-02 1999-08-19 Cargill Inc Papier mit einer beschichtung aus schmelzstabilem polymer und dessen verfahren zur herstellung
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
FR2713933B1 (fr) * 1993-12-16 1996-02-02 Rhone Merieux Méthode de superovulation des femelles bovines, méthode de mise en anoestrus et kit approprié.
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU722884B2 (en) * 1996-01-24 2000-08-10 United States Government Represented By The Secretary Of The Army Novel "burst-free" sustained release poly-(lactide/glycolide) microspheres
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE69714279T2 (de) 1996-10-15 2003-03-06 Janssen Pharmaceutica Nv Verfahren zur Herstellung eines Zwischenprodukts in der Cisapridsynthese
ATE272394T1 (de) * 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
AU4390200A (en) * 1999-02-19 2000-09-04 Bioserv Ag Biodegradable composite material for the production of microcapsules
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
JP5046447B2 (ja) 2000-08-07 2012-10-10 和光純薬工業株式会社 乳酸重合体及びその製造方法
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
CN1278675C (zh) 2001-07-10 2006-10-11 佳能株式会社 含聚羟基烷醇酸酯的粒状体及其制备方法
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
ES2282904T3 (es) 2003-09-12 2007-10-16 Wyeth Barras solidas de fosfato calcico inyectables para el suministro de proteinas osteogenicas.
ES2375802T3 (es) 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US8367038B2 (en) 2004-05-23 2013-02-05 HMI Medical Innovations, LLC Therameutin modulators
US9345911B2 (en) * 2004-08-04 2016-05-24 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US8173148B2 (en) * 2004-11-10 2012-05-08 Tolmar Therapeutics, Inc. Stabilized polymeric delivery system comprising a water-insoluble polymer and an organic liquid
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
ES2827247T3 (es) 2005-06-21 2021-05-20 Xoma Us Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
JP5072057B2 (ja) * 2005-08-22 2012-11-14 東ソー株式会社 微小流路構造体を用いたマイクロカプセルの製造方法
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
GEP20125597B (en) 2006-12-18 2012-08-10 Takeda Pharmaceutical Sustained-release composition and production method thereof
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
CA2692171C (en) 2007-06-22 2019-10-22 Randolph Watnick Methods and uses thereof of prosaposin
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
NZ595204A (en) 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CA2822026C (en) 2009-12-17 2018-06-12 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
SG10201408508YA (en) 2009-12-23 2015-02-27 Defiante Farmacêutica S A Combination composition useful for treating cardiovascular diseases
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF
ES2383271B1 (es) 2010-03-24 2013-08-01 Lipotec S.A. Procedimiento de tratamiento de fibras y/o materiales textiles
US9993019B2 (en) * 2010-03-26 2018-06-12 Philip Morris Usa Inc. Method for making particle of a hydrophobic additive and a polysaccharide coating and tobacco products containing particle of a hydrophobic additive and a polysaccharide coating
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
WO2013028541A1 (en) 2011-08-19 2013-02-28 Children's Medical Center Corporation Vegf-binding protein for blockade of angiogenesis
DE102011114864A1 (de) * 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
CN102511790B (zh) * 2011-12-05 2013-07-24 山东好当家海洋发展股份有限公司 一种水产蛋白肽微胶囊的制备方法
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
EP2793921B1 (en) 2011-12-22 2019-04-24 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
EP2833740B1 (en) 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
JP6537980B2 (ja) 2013-02-28 2019-07-03 プロノヴァ・バイオファーマ・ノルゲ・アーエスPronova BioPharma Norge AS 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
WO2015057834A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
CN111315365A (zh) 2017-09-26 2020-06-19 纳奥米有限公司 用于通过双乳液技术制备微粒的方法
MX2022001732A (es) 2019-08-12 2022-05-06 Purinomia Biotech Inc Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
CN110585170A (zh) * 2019-09-17 2019-12-20 南京赛弗斯医药科技有限公司 一种采用3d打印制备的醋酸特利加压素注射用缓释微球及其制备方法
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CN112367997B (zh) 2019-12-31 2023-12-19 广州帝奇医药技术有限公司 一种叔胺药物组合物及其产业化批量制备方法
JP2024517759A (ja) 2021-04-28 2024-04-23 ミノトール セラピューティクス インコーポレイテッド ヒト化キメラウシ抗体および使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5324423B2 (ja) * 1972-04-29 1978-07-20
JPS5017525A (ja) * 1973-06-14 1975-02-24
JPS5035158A (ja) * 1973-07-24 1975-04-03
JPS5749532B2 (ja) * 1974-03-19 1982-10-22
JPS5726506B2 (ja) * 1974-03-08 1982-06-04
JPS5314072B2 (ja) * 1973-09-29 1978-05-15
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
CH649217A5 (de) * 1977-08-25 1985-05-15 Sandoz Ag Bromocriptin enthaltende mikrokapseln.
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone

Also Published As

Publication number Publication date
EP0052510B2 (en) 1994-10-19
DE3175230D1 (en) 1986-10-02
ZA817973B (en) 1983-07-27
IL64298A0 (en) 1982-02-28
EP0052510A3 (en) 1982-09-08
ATE21624T1 (de) 1986-09-15
EP0052510A2 (en) 1982-05-26
CA1176565A (en) 1984-10-23
SG94487G (en) 1988-05-06
JPH0440329B2 (ja) 1992-07-02
NZ198982A (en) 1985-05-31
IE812695L (en) 1982-05-18
NL930001I2 (nl) 1997-05-01
AU556754B2 (en) 1986-11-20
MY8700835A (en) 1987-12-31
JPS57118512A (en) 1982-07-23
IL64298A (en) 1985-07-31
EP0052510B1 (en) 1986-08-27
IE52003B1 (en) 1987-05-13
AU7756081A (en) 1982-05-27
DE52510T1 (de) 1986-03-20
NL930001I1 (nl) 1993-02-16
PH19942A (en) 1986-08-14

Similar Documents

Publication Publication Date Title
DE3175230D1 (en) Microencapsulation of water soluble polypeptides
IE872851L (en) Method of administering bioactive agents to peyer's patch
MX243090B (en) Poly(vinylamine)-based superabsorbent gels and method of manufacturing the same
NZ226858A (en) Method of solidifying or encapsulating material in an aqueous medium using polymer particles capable of absorbing water
IL68426A (en) Biodegradable amphipathic block copolymers,their preparation and continuous release pharmaceutical and veterinary compositions comprising them
ES2046083A1 (es) Procedimiento para preparar composiciones de liberacion prolongada.
CA2074322A1 (en) A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same
CA2215495A1 (en) Environmentally friendly chewing gum compositions containing elastic protein-based polymers
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
MY125770A (en) Variable release microcapsules
PL310072A1 (en) Small-diameter microcapsules, method of making them and their applications
EP0381529A3 (en) Air freshener
BR9104426A (pt) Metodo para impedir a alogmeracao de po,agente anti-aglomeracao e po
IL83480A0 (en) Water soluble complex of a poly(vinylpyrrolidone)copolymer and d-threo(1,1'-dihydroxy-1-p-nitrophenyl-isopropyl)dichloroacetamide
DE69825769D1 (de) Eingekapselte wasserdispergierbare perfluoroetherpolymere
Kryzhavskii et al. Properties of Network Polymers Deformed in the High-Elastic State
CA2189254A1 (en) Modulated release from biocompatible polymers

Legal Events

Date Code Title Description
PE Patent expired